Needham & Company Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM) Following Positive Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities
August 7, 2019 7:02 AM EDT-- Both studies met primary and all key secondary endpoints with statistically significant and clinically meaningful results in reductions of weight and hunger --
-- Rhythm on track to complete rolling NDA submission to the FDA for both POMC and LEPR deficiency obesities in 4Q19 or 1Q20 --
-- Data from placebo withdrawal period provide evidence of drug action, validate clinical effect --
... More